Sacituzumab govitecan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sacituzumab govitecan
Accession Number
DB12893
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Sacituzumab govitecan has been used in trials studying the treatment of Breast Cancer, Cervical Cancer, Renal Cell Cancer, Colorectal Cancer, and Esophageal Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
IMMU-132
Categories
UNII
M9BYU8XDQ6
CAS number
1491917-83-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Sacituzumab govitecan.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Sacituzumab govitecan.
AbrilumabThe risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Sacituzumab govitecan.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Sacituzumab govitecan.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Sacituzumab govitecan.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Sacituzumab govitecan.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Sacituzumab govitecan.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Sacituzumab govitecan.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911403
Wikipedia
Sacituzumab_govitecan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentGlioblastomas1
1, 2Active Not RecruitingTreatmentBreast Cancer Metastatic / Cervical Cancers / Colorectal Cancers / Endometrial Cancers / Esophageal Cancers / Follicular Thyroid Cancer / Gastric Adenocarcinoma / Glioblastoma Multiforme (GBM) / Head and Neck Cancers- Squamous Cell / Hepatocellular,Carcinoma / Hormone-Refractory Prostate Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian Epithelial Cancer / Pancreatic Ductal Adenocarcinoma / Renal Cell Adenocarcinoma / Triple Negative Breast Cancer (TNBC) / Urinary Bladder Neoplasms1
1, 2Not Yet RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentCancer of the Ovary / Transitional Cell Carcinoma / Triple-Negative Breast Cancer (TNBC) / Tumors, Solid1
2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentEndometrial Cancers / Head and Neck Squamous Cell Carcinoma (HNSCC) / Hepatocellular,Carcinoma / Lung Cancer Small Cell Lung Cancer (SCLC) / Metastatic Non-Small Cell Lung Carcinoma1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentTransitional Cell Carcinoma1
3Active Not RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 19:04 / Updated on September 02, 2019 19:49